<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7432271\results\search\country\results.xml">
  <result pre="analysis of COVID-19 patients admitted to a hospital in Wuhan," exact="China" post="reported that patients showed elevated plasma concentrations of other"/>
  <result pre="common comorbidity varied among the seven countries reviewed, as follows:" exact="China" post="(hypertension 39.5%), South Korea (cardiovascular disease 25.6%), Italy (hypertension"/>
  <result pre="among the seven countries reviewed, as follows: China (hypertension 39.5%)," exact="South Korea" post="(cardiovascular disease 25.6%), Italy (hypertension 35.9%), USA (hypertension 38.9%),"/>
  <result pre="as follows: China (hypertension 39.5%), South Korea (cardiovascular disease 25.6%)," exact="Italy" post="(hypertension 35.9%), USA (hypertension 38.9%), Mexico, (other 42.3%), UK"/>
  <result pre="35.9%), USA (hypertension 38.9%), Mexico, (other 42.3%), UK (hypertension 27.8%)," exact="Iran" post="(diabetes 35.0%); diabetes was the second most common comorbidity"/>
  <result pre="in treatment of the first patient diagnosed with COVID-19 in" exact="the United States" post="[102]. In order to further investigate the efficacy and"/>
  <result pre="treatment of the first patient diagnosed with COVID-19 in the" exact="United States" post="[102]. In order to further investigate the efficacy and"/>
  <result pre="trials in severe and mild/moderate respiratory infections by SARS-CoV-2 in" exact="the United States" post="and two in China have been commenced [103]. The"/>
  <result pre="in severe and mild/moderate respiratory infections by SARS-CoV-2 in the" exact="United States" post="and two in China have been commenced [103]. The"/>
  <result pre="infections by SARS-CoV-2 in the United States and two in" exact="China" post="have been commenced [103]. The first randomized controlled clinical"/>
  <result pre="[103]. The first randomized controlled clinical trial of remdesivir in" exact="the United States," post="known as the Adaptive COVID-19 Treatment Trial, enrolled 1063"/>
  <result pre="The first randomized controlled clinical trial of remdesivir in the" exact="United States," post="known as the Adaptive COVID-19 Treatment Trial, enrolled 1063"/>
  <result pre="another cohort of 53 patients hospitalized for severe COVID-19 in" exact="the United States," post="Europe, Canada or Japan a 10-day course of remdesivir"/>
  <result pre="cohort of 53 patients hospitalized for severe COVID-19 in the" exact="United States," post="Europe, Canada or Japan a 10-day course of remdesivir"/>
  <result pre="patients hospitalized for severe COVID-19 in the United States, Europe," exact="Canada" post="or Japan a 10-day course of remdesivir resulted in"/>
  <result pre="for severe COVID-19 in the United States, Europe, Canada or" exact="Japan" post="a 10-day course of remdesivir resulted in clinical improvement"/>
  <result pre="in 237 laboratory-confirmed SARS-CoV-2 infected patients, from ten hospitals in" exact="China" post="(NCT04257656), revealed that time to clinical improvement was not"/>
  <result pre="hospitalized with severe suspected or laboratory-confirmed COVID-19 was approved by" exact="the US" post="FDA [4]. 8.1.2. Lopinavir/Ritonavir Lopinavir/Ritonavir (LPV/r) is a coformulation"/>
  <result pre="of six patients with confirmed COVID-19 infection in Korea and" exact="China" post="showed a significant decrease in SARS-CoV-2 viral load and"/>
  <result pre="caution when interpreting such results [80,110,111]. In another study in" exact="Singapore" post="the efficacy of LPV/r was evaluated on five patients"/>
  <result pre="10 ongoing clinical trials have been registered from China, Korea," exact="Thailand" post="and Hong Kong to evaluate efficacy of LPV/r for"/>
  <result pre="clinical trials have been registered from China, Korea, Thailand and" exact="Hong Kong" post="to evaluate efficacy of LPV/r for the treatment of"/>
  <result pre="been reported from limited clinical experiences. An open-label study in" exact="China" post="compared the effects of favipiravir plus interferon-Î± with LPV/r"/>
  <result pre="results favipiravir was approved as the first anti-COVID-19 drug in" exact="China" post="[121]. Another randomized clinical trial compared the effect of"/>
  <result pre="treatment of COVID-19 is not recommended. An ongoing trial in" exact="China" post="(ChiCTR2000029387) is evaluating the efficacy and safety of ribavirin"/>
  <result pre="various enveloped and non-enveloped viruses and is widely used in" exact="Russia" post="and China [133]. Arbidol displays antiviral activity in vitro"/>
  <result pre="and non-enveloped viruses and is widely used in Russia and" exact="China" post="[133]. Arbidol displays antiviral activity in vitro and/or in"/>
  <result pre="are investigating the efficacy of arbidol on COVID-19 patients in" exact="China" post="and USA (NCT04260594, NCT04255017). Four clinical trials are comparing"/>
  <result pre="exocrine pancreatic enzyme inhibition [138]. Camostat mesylate was developed in" exact="Japan" post="in the 1980s but very little data from outside"/>
  <result pre="Japan in the 1980s but very little data from outside" exact="Japan" post="is available. Some coronaviruses (SARS-CoV, MERS-CoV) and influenza virus"/>
  <result pre="guanidinobenzoate dimethanesulfonate) is a synthetic serine protease inhibitor available in" exact="Japan" post="since 1986 that has been approved for the treatment"/>
  <result pre="administered shortly after the appearance of symptoms [177]. In a" exact="Hong Kong" post="study, 80 SARS patients who were administrated convalescent plasma"/>
  <result pre="patients to three health care workers with SARS infection in" exact="Taiwan" post="resulted in survival of all three patients, a decrease"/>
  <result pre="administration of convalescent plasma to three patients with MERS in" exact="South Korea" post="showed the presence of neutralizing antibodies in only two"/>
  <result pre="demonstrated anti-SARS-CoV-2 activity of convalescent plasma from six patients in" exact="China" post="who had recovered; transfusion of the plasma to a"/>
  <result pre="COVID-19 [182,183,184,185,186,187,188,189], joining other registered trials in China, Columbia, Iran," exact="Mexico" post="and Baylor Research Institute in USA [182,183,184,185,186,187,188,189]. 9.2. Intravenous"/>
  <result pre="cohort study of 325 critically unwell adult COVID-19 patients in" exact="China" post="who were exposed to IVIG, demonstrated that although early"/>
  <result pre="In a study on 20 patients with COVID-19 in Anhui," exact="China" post="more than 75% of patients admitted to ICU who"/>
  <result pre="and favipiravir, a randomized controlled trial has been registered in" exact="China" post="(ChiCTR2000030894) [201]. Sarilumab (Kevzara) is another IL-6 receptor antagonist"/>
  <result pre="(Qletli) for their safety and efficacy in COVID-19 treatment in" exact="China" post="(ChiCTR2000030089, ChiCTR2000030580). However, upper respiratory tract infections and reactivation"/>
  <result pre="registered using camrelizumab for treatment of critical COVID-19 patients in" exact="China" post="[209]. Omalizumab is an IgG1 humanized anti IgE monoclonal"/>
  <result pre="University of Sydney; National Health and Medical Research Council of" exact="Australia" post="(NHMRC) Program Grant (1053206) and Project grants (APP1107178 and"/>
  <result pre="search and a narrative review with a special reference to" exact="India" post="and other developing countriesDiabetes Metab. Syndr. Clin. Res. Rev.20201424124610.1016/j.dsx.2020.03.01132247211"/>
  <result pre="Antibodies Produced by Transchromosomal Cattle Provide Partial Protection Against Lethal" exact="Zaire" post="Ebolavirus Challenge in Rhesus MacaquesJ. Infect. Dis.2018218S658S66110.1093/infdis/jiy43030053153 174.ZhangJ.-S.ChenJ.-T.LiuY.-X.ZhangZ.-S.GaoH.LiuY.WangX.NingY.LiuY.-F.GaoQ.et al.A"/>
  <result pre="for severe acute respiratory syndrome among healthcare workers in a" exact="Taiwan" post="hospitalJ. Antimicrob. Chemother.20055691992210.1093/jac/dki34616183666 180.KoJ.-H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.KimY.-J.ParkJ.K.ChungC.R.KangE.-S.et al.Challenges of convalescent plasma infusion"/>
 </snippets>
</snippetsTree>
